On June 20, 2018 NewLink Genetics Corporation (NASDAQ:NLNK) reported that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105, a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors, will be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO) in Denver, Colorado (Press release, NewLink Genetics, JUN 20, 2018, View Source [SID1234527407]). The presentation session and time are noted below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Session 1: IMMU-25 – Radio-immunotherapy using the IDO pathway inhibitor indoximod for children with newly-diagnosed DIPG, to be presented by Theodore S. Johnson, M.D., Ph.D., Georgia Cancer Center, Augusta University, Sunday, July 1, 5:00PM – 6:30PM MT, Hyatt Regency Denver

About Indoximod
Indoximod is an investigational, orally available small molecule targeting the IDO pathway. The IDO pathway is a key immuno-oncology target involved in regulating the tumor microenvironment and immune escape. Indoximod is being evaluated in combination with treatment regimens including chemotherapy, radiation, checkpoint blockade and cancer vaccines across multiple indications such as AML, DIPG and melanoma.